GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » Other Income (Expense)

Heidelberg Pharma AG (LTS:0QW5) Other Income (Expense) : €2.00 Mil (TTM As of Aug. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG Other Income (Expense)?

Heidelberg Pharma AG's other income expense for the Heidelberg Pharma AG's pretax income for the three months ended in Aug. 2024 was €0.14 Mil. Its other income expense for the trailing twelve months (TTM) ended in Aug. 2024 was €2.00 Mil.


Heidelberg Pharma AG Other Income (Expense) Historical Data

The historical data trend for Heidelberg Pharma AG's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Other Income (Expense) Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.21 0.15 1.22 6.89

Heidelberg Pharma AG Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 -0.37 0.59 1.64 0.14

Heidelberg Pharma AG Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG  (LTS:0QW5) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Heidelberg Pharma AG Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines